Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar Fiskhus (71.93) Submitted: 8/3/2012 7:59:56 AM : Outperform Start Price: $2.50 DYAX Score: +9.01

T$x Up & Buy

Featured Broker Partners


Advertisement